Ansaldi, F.; Pugh, S.; Amicizia, D.; Di Virgilio, R.; Trucchi, C.; Orsi, A.; Zollo, A.; Icardi, G.
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens 2020, 9, 76.
https://doi.org/10.3390/pathogens9020076
AMA Style
Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A, Zollo A, Icardi G.
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens. 2020; 9(2):76.
https://doi.org/10.3390/pathogens9020076
Chicago/Turabian Style
Ansaldi, Filippo, Sarah Pugh, Daniela Amicizia, Roberto Di Virgilio, Cecilia Trucchi, Andrea Orsi, Alessandro Zollo, and Giancarlo Icardi.
2020. "Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy" Pathogens 9, no. 2: 76.
https://doi.org/10.3390/pathogens9020076
APA Style
Ansaldi, F., Pugh, S., Amicizia, D., Di Virgilio, R., Trucchi, C., Orsi, A., Zollo, A., & Icardi, G.
(2020). Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens, 9(2), 76.
https://doi.org/10.3390/pathogens9020076